Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
NCT ID NCT07725796
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance doses. The main goals are to check the drug's safety and tolerability, and to find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a biologic drug called UGN-501, given directly into the bladder through a catheter
- What this could lead to
- If this early trial shows UGN-501 is safe and tolerable, it could lead to a new treatment option for people with bladder cancer that keeps coming back.
- What could go wrong
- This is a very early phase 1 trial with only 30 participants, so it is primarily testing safety, not effectiveness. The drug may cause side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
East Valley Urology Center of Arizona
Queen Creek, Arizona, 85140, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ichan School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Michael G Oefelein Clinical Trials
Bakersfield, California, 93301, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Carolinas
Myrtle Beach, South Carolina, 29572, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPNT Research Institute
Arlington, Texas, 76017, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania-Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Urology Austin
Austin, Texas, 78759, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Urology Center of Southern California
Murrieta, California, 92563, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common vitamin restore immunotherapy power after antibiotics?
- Combining two drugs may tackle bladder cancer that resists standard therapy
- Could less be more? bladder cancer trial tests stopping immunotherapy after tumors vanish
- New combo aims to wipe out rare bladder cancer before surgery
- New drug duo aims to stop bladder cancer from coming back
- Could bladder bacteria trigger cancer? new study investigates